Quellenangaben: Tierversuche aus medizinisch-wissenschaftlicher Sicht

1. Packer, M.; Carver, J. R.; Rodeheffer, R. J.; Ivanhoe, R. J.; DiBianco, R.; Zeldis, S. M.; Hendrix, G. H.; Bommer, W. J.; Elkayam, U.; Kukin, M. L. und et, a. l..: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med, 1991, 325(21), S.1468-1475

2. Couzin, J.: Estrogen research. The great estrogen conundrum. Science, 2003, 302(5648), S.1136-1138

3. Freeberg, FE; Hooker, DT und Griffith, JF: Correlation of animal eye test data with human experience for household products: An update. Journal of Toxicology - Cutaneous and Ocular Toxicology, 1986, 5, S.115-123

4. Langley, G und Fisher, G: New Perspectives in Cosmetics Toxicology: Non-animal Tier-Testing Strategies. International Fund for Animal Welfare, London, 1995

5. Fano, A: Lethal Laws: Animal Testing, Human Health and Environmental Policy. Zed Books, London, 1997, S.157-159

6. Bailey, J; Knight, A und Balcombe, J: The future of teratology research is in vitro. Biogenic Amines, 2005, 19(2), S.97-145

7. Hartinger, Werner: Experiments on Animals are scientifically unacceptable / Tierversuche sind wissenschaftlich nicht verwertbar. Ehlers Verlag, 1993

8 Die Nachtseite des Wirtschaftswunders. Zum Einschlafen nahm 1961 jeder dritte Deutsche Contergan: Eine Bilanz nach 40 Jahren. Frankfurter Allgemeine Zeitung (FAZ)

9. Thomann, Klaus-Dieter: DIE CONTERGAN-KATASTROPHE. Die trügerische Sicherheit der «harten» Daten. Deutsches Ärzteblatt, 2007, 104(41), S.2778-2782

10. Stillperiode, Beratungsstelle fürMedikamentenanwendunginSchwangerschaftund: Speziesunterschiede der Teratogenität von Thalidomid. Klinik für Frauenheilkunde und Geburtshilfe der Friedrich-Schiller-Universität Jena, Jena, 2006

11. Topol, E. J.: Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med, 2004, 351(17), S.1707-1709

12. biopta: Human Pharmacological Services. In Vitro Pharmacology Screening in Human Tissue. 2008

13. Suntharalingam, G.; Perry, M. R.; Ward, S.; Brett, S. J.; Castello-Cortes, A.; Brunner, M. D. und Panoskaltsis, N.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med, 2006, 355(10), S.1018-1028

14.  Drugs tests on trial. Nature, 2006, 440(7087), S.970

15. Lazarou, J.; Pomeranz, B. H. und Corey, P. N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279(15), S.1200-1205

16. Wester, K.; Jonsson, A. K.; Spigset, O.; Druid, H. und Hagg, S.: Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol, 2008, 65(4), S.573-579

17. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A. K.; Walley, T. J.; Farrar, K.; Park, B. K. und Breckenridge, A. M.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 2004, 329(7456), S.15-19

18 Merz' Zustand «besser als erträumt». Tages Anzeiger

19. Gardner, MB und Luciw, PA: Animal Models of AIDS. FASEB Journal, 1989, 3, S.2593-2606

20. O'Neil, S. P.; Novembre, F. J.; Hill, A. B.; Suwyn, C.; Hart, C. E.; Evans-Strickfaden, T.; Anderson, D. C.; deRosayro, J.; Herndon, J. G.; Saucier, M. und McClure, H. M.: Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis, 2000, 182(4), S.1051-1062

21. Gauduin, M. C.; Parren, P. W.; Weir, R.; Barbas, C. F.; Burton, D. R. und Koup, R. A.: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med, 1997, 3(12), S.1389-1393

22. Diseases, National InstituteofAllergyandInfectious: Clinical Trials of HIV Vaccines. URL: http://niaid.nih.gov/factsheets/clinrsch.htm, National Institutes of Health. U.S. Department of Health and Human Services, Abruf: 25.09.2008

23. DeVita Jr., VT; Hellman, S und Rosenberg, SA: AIDS Etiology, Diagnosis, Treatment and Prevention. JB Lippincott, Philadelphia, 1992

24. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W. und Broder, S.: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A, 1985, 82(20), S.7096-7100

25. Soudeyns, H.; Yao, X. I.; Gao, Q.; Belleau, B.; Kraus, J. L.; Nguyen-Ba, N.; Spira, B. und Wainberg, M. A.: Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother, 1991, 35(7), S.1386-1390

26. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A. und et, a. l..: Rational design of peptide-based HIV proteinase inhibitors. Science, 1990, 248(4953), S.358-361

27. Hoffmann, Christian; Rockstroh, Jürgen K und Kamps, Bernd Sebastian: HIV.NET 2008. Steinhäuser Verlag, Wuppertal, 2008, S.104-108

28. Stott, J. und Almond, N.: Assessing animal models of AIDS. Nat Med, 1995, 1(4), S.295-297

29. Weinhouse, S.: National Cancer Act of 1971--an editorial. Cancer Res, 1972, 32(4), S.i-ii

30. Dulbecco, R.: A turning point in cancer research: sequencing the human genome. Science, 1986, 231(4742), S.1055-1056

31 The case for understanding the molecular nature of cancer: Some recent findings and their implications. Medical News

32. Bross, I: Crimes of Official Science. Biomedical Metatechnology, Buffalo, 1987

33. Hahn, W. C.; Counter, C. M.; Lundberg, A. S.; Beijersbergen, R. L.; Brooks, M. W. und Weinberg, R. A.: Creation of human tumour cells with defined genetic elements. Nature, 1999, 400(6743), S.464-468

34. DOLL, R. und HILL, A. B.: The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J, 1954, 1(4877), S.1451-1455

35. Brecher, R: The Consumers Union Report on Smoking and the Public Interest. Consumers Union, Mount Vernon, 1963

36. Northrup, E: Men, mice and smoking. In: Hrsg. unbekannt: Science Looks at Smoking. Cowar-McCann, New York, 1957, S.133

37. Ahnen, D. J.: Are animal models of colon cancer relevant to human disease. Dig Dis Sci, 1985, 30(12 Suppl), S.103S-106S

38. Pories, S. E.; Ramchurren, N.; Summerhayes, I. und Steele, G.: Animal models for colon carcinogenesis. Arch Surg, 1993, 128(6), S.647-653

39. Ames, BN und Gold, LS: Falsche Annahmen über die Zusammenhänge zwischen der Umweltverschmutzung und der Entstehung von Krebs. Angewandte Chemie, 1990, 102, S.1233-1246

40. Vinylchlorid. In: Hrsg. unbekannt: Pschyrembel. Klinisches Wörterbuch. Walter de Gruyter GmbH & Co. KG, 2001

41. Harrison, D. F.: Fear of cancer. Clin Oncol, 1980, 6(1), S.1-2

42. (UNAIDS), Joint UnitedNationsProgrammeonHIV&AIDS: 2008 Report on the global AIDS epidemic. Geneva, 2008, S.30-32

43. Beeson, P. B.: The growth of knowledge about a disease: hepatitis. Am J Med, 1979, 67(3), S.366-370

44. Good, R. A.: Presidential address to the American Association of Immunologists, delivered in Anaheim, California, April 13, 1976. Runestones in immunology: inscriptions to journeys of discovery and analysis. J Immunol, 1976, 117(5 Pt 1), S.1413-1428

45. Good, R. A.: Keystones. Journal of Clinical Investigation, 1968, 47, S.1466-1471

46. Heimlich, H. J. und Patrick, E. A.: The Heimlich maneuver. Best technique for saving any choking victim's life. Postgrad Med, 1990, 87(6), S.38-48, 53

47. Sitaram, N und Gershon, S: Animal models to clinical testing – promises and pitfalls. In: Hrsg. unbekannt: Progress in Neuropsychopharmacology, Biology and Psychiatry. 1983, S.227-228

48. Davis, JM: Antipsychotic drugs. In: Kaplan, HI et al. : Comprehensive Textbook of Psychiatry. William and Wilkins, Baltimore, 1985

49. DOYLE, J. T.; DAWBER, T. R.; KANNEL, W. B.; KINCH, S. H. und KAHN, H. A.: THE RELATIONSHIP OF CIGARETTE SMOKING TO CORONARY HEART DISEASE; THE SECOND REPORT OF THE COMBINED EXPERIENCE OF THE ALBANY, NY. AND FRAMINGHAM, MASS. STUDIES. JAMA, 1964, 190, S.886-890

50. KANNEL, W. B.; DAWBER, T. R.; THOMAS HE, J. r. und MCNAMARA, P. M.: COMPARISON OF SERUM LIPIDS IN THE PREDICTION OF CORONARY HEART DISEASE. FRAMINGHAM STUDY INDICATES THAT CHOLESTEROL LEVEL AND BLOOD PRESSURE ARE MAJOR FACTORS IN CORONARY HEART DISEASE; EFFECT OF OBESITY AND CIGARETTE SMOKING ALSO NOTED. R I Med J, 1965, 48, S.243-250

51. Lewis, T: Clinical Science: for treating atrial fibrillation. Shaw and Sons Ltd., 1934

52. Sneader, W: Drug Discovery: the Evolution of Modern Medicine. For treating heart failure. Wiley, 1985

53. Bellet, S: Clinical Disorders of the Heart Beat. Lea and Febiger, 1971

54. Vaughan Williams, EM: Antiarrhythmic Action and the Puzzle of Perhexiline. Academic Press, 1980

55. Snell, ES: Pharmacy International, 1986,(Feb), S.33-37

56. PEARSON, O. H.; ELIEL, L. P. und et, a. l..: Adrenocorticotropic hormone- and cortisone-induced regression of lymphoid tumors in man; a preliminary report. Cancer, 1949, 2(6), S.943-945

57. Boesen, E: Cytotoxic Drugs in the Treatment of Cancer. Edward Arnold, London, 1969, S.24

58. Coley, WB: A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate, 1893, 8, S.278-286

59. Caldwell, A: Origins of Psychopharmacology: From CPZ to LSD. Charles C Thomas, Springfield, 1970

60. Lehmann, HE und Kline, NS: Clinical discoveries with antidepressant drugs. In: Parnham, MJ et al. : Discoveries in Pharmacology. Elsevier, New York, 1983, S.209-221

61. Sulser, F und Mishra, R: The discovery of tricyclic antidepressants and their mode of action. In: Parnham, MJ et al. : Discoveries in Pharmacology. Elsevier, New York, 1983, S.233-247

62. Silverman, W. A.: The schizophrenic career of a «monster drug». Pediatrics, 2002, 110(2 Pt 1), S.404-406

63. GOOD, R. A.; VARCO, R. L.; AUST, J. B. und ZAK, S. J.: Transplantation studies in patients with agammaglobulinemia. Ann N Y Acad Sci, 1957, 64(5), S.882-924; discussion, 924

64. Palca, J.: Insights from broken brains. Science, 1990, 248(4957), S.812-814

65. Wiebers, D. O.; Adams HP, J. r. und Whisnant, J. P.: Animal models of stroke: are they relevant to human disease? Stroke, 1990, 21(1), S.1-3

66. Koch, Robert: British Medical Journal, 1884, S.454

67. Altmann, LK: Who goes first? The story of self-experimentation. Random House, New York, 1987

68. Wilding, I. R. und Bell, J. A.: Improved early clinical development through human microdosing studies. Drug Discov Today, 2005, 10(13), S.890-894

69. Bauer, M.; Wagner, C. C. und Langer, O.: Microdosing studies in humans: the role of positron emission tomography. Drugs R D, 2008, 9(2), S.73-81

70. Persönliche Korrespondenz mit dem Hersteller HµREL Corporation über HµRELs. 2008

71. Herstellerinformationen zum Entelos Virtual Patient. http://www.entelos.com

72. Informationen zum NSR Physiome Project. http://www.physiome.org/

73. Office, US GeneralAccounting: Cancer Patient Survival: What progress has been made? General Accounting Office, Washington DC, 1987

74. DiMasi, J. A.; Hansen, R. W. und Grabowski, H. G.: The price of innovation: new estimates of drug development costs. J Health Econ, 2003, 22(2), S.151-185

75. U.S. Congress, Office of Technology Assessment: Alternatives to animal use in research, testing and education. U.S. Government Printing Office, Washington, DC, 1986, S.250-251

76. Innovation Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services. Food and Drug Administration (FDA), 2004, S.8

77. Crawford, Lester M: Speech before PhRMA Annual Meeting. FDA (U.S. Food and Drug Administration), 2004

78. FDA Drug Review: Postapproval Risks 1975-1985. U.S. General Accounting Office, Washington D.C.

79. Medicine, Physicians CommitteeforResponsible: Ethics in Medical Student Education. URL: http://www.pcrm.org/resch/meded/index.html, Abruf: 27.09.2008

80. N.V., Crucell: Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing. 2008

81. (Hg.), Vereinigung Ärzte gegenTierversuchee.V.: Gesundheit & Fortschritt in der Medizin - ohne Tierversuche. , S.14


82. Hejazi S. Gefäßchirurgie -- ein historischer Rückblick. Hessisches Ärzteblatt 2001(8/2001):379-381


Flyer: http://www.agstg.ch/AG-STG-Infomaterial.html